Tags

Type your tag names separated by a space and hit enter

The need for better control of secondary hyperparathyroidism.
Nephrol Dial Transplant. 2004 Aug; 19 Suppl 5:V15-19.ND

Abstract

Secondary hyperparathyroidism (SHPT), a frequent complication of chronic kidney disease, develops in response to an imbalance in the serum levels of calcium, phosphorus and vitamin D as a result of altered metabolism. Raised serum levels of parathyroid hormone (PTH) and calcium-phosphorus product have a major effect on morbidity and mortality in dialysis patients. The new Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines, formulated by the National Kidney Foundation in the USA, propose strict targets for the control of serum levels of PTH, calcium and phosphorus. Meeting these targets will be a challenge for clinicians, because the traditional therapies for SHPT, such as vitamin D sterols and calcium-based phosphate binders, often exacerbate mineral imbalances. Results from a number of recent studies indicate that the majority of haemodialysis patients currently do not meet these new targets. Thus, there is a definite need to improve PTH, calcium and phosphate management of dialysis patients to reduce the incidence of uraemic bone disease and related disturbances of mineral metabolism as well as their unacceptably high cardiovascular morbidity and mortality.

Authors+Show Affiliations

Department of Nephrology and Dialysis, Ospedale A. Manzoni, 23900 Lecco, Italy. nefrologia@ospedale.lecco.it

Pub Type(s)

Journal Article

Language

eng

PubMed ID

15284355

Citation

Locatelli, Francesco. "The Need for Better Control of Secondary Hyperparathyroidism." Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association, vol. 19 Suppl 5, 2004, pp. V15-19.
Locatelli F. The need for better control of secondary hyperparathyroidism. Nephrol Dial Transplant. 2004;19 Suppl 5:V15-19.
Locatelli, F. (2004). The need for better control of secondary hyperparathyroidism. Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association, 19 Suppl 5, V15-19.
Locatelli F. The Need for Better Control of Secondary Hyperparathyroidism. Nephrol Dial Transplant. 2004;19 Suppl 5:V15-19. PubMed PMID: 15284355.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The need for better control of secondary hyperparathyroidism. A1 - Locatelli,Francesco, PY - 2004/7/31/pubmed PY - 2004/12/16/medline PY - 2004/7/31/entrez SP - V15 EP - 19 JF - Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association JO - Nephrol. Dial. Transplant. VL - 19 Suppl 5 N2 - Secondary hyperparathyroidism (SHPT), a frequent complication of chronic kidney disease, develops in response to an imbalance in the serum levels of calcium, phosphorus and vitamin D as a result of altered metabolism. Raised serum levels of parathyroid hormone (PTH) and calcium-phosphorus product have a major effect on morbidity and mortality in dialysis patients. The new Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines, formulated by the National Kidney Foundation in the USA, propose strict targets for the control of serum levels of PTH, calcium and phosphorus. Meeting these targets will be a challenge for clinicians, because the traditional therapies for SHPT, such as vitamin D sterols and calcium-based phosphate binders, often exacerbate mineral imbalances. Results from a number of recent studies indicate that the majority of haemodialysis patients currently do not meet these new targets. Thus, there is a definite need to improve PTH, calcium and phosphate management of dialysis patients to reduce the incidence of uraemic bone disease and related disturbances of mineral metabolism as well as their unacceptably high cardiovascular morbidity and mortality. SN - 0931-0509 UR - https://www.unboundmedicine.com/medline/citation/15284355/The_need_for_better_control_of_secondary_hyperparathyroidism_ L2 - https://academic.oup.com/ndt/article-lookup/doi/10.1093/ndt/gfh1051 DB - PRIME DP - Unbound Medicine ER -